The last two webinars of our webinar series on Clostridioides difficile are on their way! Within the past five and following two webinars we are developing a full picture of CDI by reviewing and discussing the latest findings with leading experts in the field of neurogastroenterology and its closest disciplines. The next webinar “Prevention of recurrence and re-infections” starts on October 12, 2022 at 4pm (CEST). Join us to learn more about the management of severe CDI and its recurrence, together with our speakers Steven Johnson and Tariq Iqbal and this time´s chair Daniel Pohl.
After a successfull 1st episode of our webinar series together with the Turkish Society of Gastroenterology (TGD) "Speed date with experts", the series resumes on Nov 7, 7pm (CET). Join us and this time´s expert Edoardo Savarino to learn more about eosinophilic oesophagitis.
"Interdisciplinary expertise at its best!" The next ESNM biennial meeting NeuroGASTRO 2023 is not far away! Save the date and meet us on Aug 31st to Sept 2nd, 2023 in beautiful Bucharest, Romania. Please note: Abstract submission for NeuroGASTRO 2023 will open January 16, 2023. Deadline Abstract submission: March 31, 2023.
The EU-funded project DISCOvERIE has reached the 50% of its timeline to position Europe as a global leader in comorbid IBS personalised medicine. The main hypothesis is that comorbid IBS represents a distinct clinical entity, arising from distorted brain-gut communication with a unique, specific, but undefined pathophysiological origin, differing from IBS alone.
UEG Meet with Presidents Meeting // July 1-2, 2022, Lisbon
The UEG Presidents and the Council and Leadership of UEG´s specialist member societies came together this summer in Lisbon to meet old and new friends and strengthen the bonds between the different societies, and visit experts in their field. ESNM President Qasim Aziz attended the event as a representative of our society and took the opportunity to share and participate in the diverse "collaborative creativity".
What a highlight! In fact two Israeli NeuroGASTRO meetings were held in June/July 2022: The annual meeting of I-NGM took place in Nazareth from June 30 to July 1. Leading national and international experts attended to exchange and discuss latest findings on esophageal diseases and particularly GERD. The semi-annual meeting of the Israel Gastroenterology Association (IGA) took place in Tel Aviv on July 19. It included a 75-minute session dedicated to I-NGM.
The third edition of IBS DAYS 2022 provided current advances and a look to future therapeutic approaches on the rapidly advancing field of irritable bowel syndrome. This GMFH article summarizes major highlights on diet and gut microbiome interactions of relevance for IBS.
"Little Brain Big Brain" extraordinary meeting 2022 Since its initiation in the late 1980s, Little Brain Big Brain has been dedicated to bring together the most promising and motivated junior scientists and clinicians in the field of functional gut brain disorders (FGBD), neurogastroenterology and motility. This year, LBBB took place in Heiligkreuztal, Germany from the 5th to 9th of September.
Graphic Abstract: Association Between Psychosocial Disorders and Gastroesophageal Reflux Disease
Gastroesophageal reflux disease (GERD) is a common upper gastrointestinal tract disorder. The main cause of GERD is a reflux of stomach and duodenum contents into the esophagus, which results in – among others – acid reflux and heartburn. It is estimated that over 1 billion people worldwide suffer from GERD.
Take part in a survey for a research study on Impedance in Esophageal Studies. The aim of the study is to evaluate the implications of esophageal impedance data obtained during esophageal manometry investigations in a brief 10 question anonymous survey.
The aim of this project is to create an European based database to investigate the role of different genetic factors that might be linked to functional dyspepsia (FD) symptoms. At present the project is looking for new centers in Europe that would like to help and are eager to recruit 50 patients or more diagnosed with functional dyspepsia as described by the Rome IV criteria and if possible 50 healthy controls during the next year.